The FDA has taken major steps toward increasing generic drug competition by releasing a list of off-patent pharmaceuticals with limited or no competition, and by prioritizing the review of abbreviated new drug applications (ANDAs) for which there are fewer than three ANDAs approved for the reference listed drug … more

Separately, the  National Institutes of Health has earmarked $21 million over the next four years to fund a network of research groups that will help build a data commons to serve as a cloud-based platform for storing, sharing, accessing, and computing biomedical data and other digital objects … more